BerGenBio ASA Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.06.21	Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting (PR Newswire)
11.06.21	Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting (PR Newswire)
18.05.21	BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients (PR Newswire)
18.05.21	BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients (PR Newswire)
19.04.21	BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients (PR Newswire)
19.04.21	BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients (PR Newswire)
06.03.21	BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021) (PR Newswire)
04.03.21	Bergenbio Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients (PR Newswire)
17.02.21	BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) (PR Newswire)
17.02.21	BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) (PR Newswire)
06.12.20	BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 (PR Newswire)
06.12.20	BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 (PR Newswire)
11.11.20	BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting (PR Newswire)
11.11.20	BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting (PR Newswire)
18.09.20	BerGenBio to Present At Sachs annual biotech In europe forum (PR Newswire)
18.08.20	BerGenBio ASA: Results for the Second Quarter and First Half of 2020 (PR Newswire)
18.08.20	BerGenBio ASA: Results for the Second Quarter and First Half of 2020 (PR Newswire)
10.08.20	BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation (PR Newswire)
10.08.20	BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation (PR Newswire)
28.07.20	Update On Bemcentinib's Involvement in Potential Treatment of COVID-19 Pandemic (PR Newswire)
28.07.20	Update On Bemcentinib's Involvement in Potential Treatment of COVID-19 Pandemic (PR Newswire)
20.07.20	BerGenBio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib (PR Newswire)
20.07.20	Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib (PR Newswire)
07.07.20	BerGenBio to Present at Digital Novel Coronavirus Investment Forum (PR Newswire)
07.07.20	BerGenBio to Present at Digital Novel Coronavirus Investment Forum (PR Newswire)
25.06.20	BerGenBio Announces Positive Interim Clinical and Translational Data from Phase II Trial of Bemcentinib in Combination with Keytruda® in Checkpoint Inhibitor Refractory NSCLC Patients (PR Newswire)
25.06.20	BerGenBio Announces Positive Interim Clinical and Translational Data from Phase II Trial of Bemcentinib in Combination with Keytruda® in Checkpoint Inhibitor Refractory NSCLC Patients (PR Newswire)
24.06.20	BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology Congress (PR Newswire)
24.06.20	BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology Congress (PR Newswire)
23.06.20	BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020 (PR Newswire)
15.06.20	BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients At Next Gen Immuno-Oncology Congress (PR Newswire)
15.06.20	BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients At Next Gen Immuno-Oncology Congress (PR Newswire)
02.06.20	BerGenBio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial (PR Newswire)
02.06.20	Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial (PR Newswire)
19.05.20	BerGenBio ASA: Results for the First Quarter 2020 (PR Newswire)
19.05.20	BerGenBio ASA: Results for the First Quarter 2020 (PR Newswire)
13.05.20	BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation (PR Newswire)
13.05.20	BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation (PR Newswire)
05.05.20	BerGenBio Raises Nok500m (€45.4m) via an Over Subscribed Private Placement (PR Newswire)
05.05.20	BerGenBio Raises Nok500m (€45.4m) via an Over Subscribed Private Placement (PR Newswire)
05.05.20	BerGenBio ASA - Private Placement Successfully Placed (PR Newswire)
29.04.20	BerGenBio's Bemcentinib Selected to be Fast-tracked as Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative (PR Newswire)
29.04.20	BerGenBio's Bemcentinib Selected to Be Fast-tracked As Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative (PR Newswire)
29.04.20	BerGenBio's Bemcentinib Selected to Be Fast-tracked As Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative (PR Newswire)
11.02.20	BerGenBio ASA: Results For The Fourth Quarter and Full Year 2019 (PR Newswire)
11.02.20	BerGenBio ASA: Results For The Fourth Quarter and Full Year 2019 (PR Newswire)
30.01.20	BerGenBio ASA - Private Placement Successfully Placed (PR Newswire)
30.01.20	BerGenBio ASA - Private Placement Successfully Placed (PR Newswire)
15.01.20	BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors (PR Newswire)
15.01.20	BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu BerGenBio ASA Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten